Medicare, Medicaid, and CLIA Programs; Clinical Laboratory Improvement Amendments of 1988 Exemption of Laboratories Licensed by the State of Washington, 59704-59706 [2013-23659]
Download as PDF
59704
Federal Register / Vol. 78, No. 188 / Friday, September 27, 2013 / Notices
C. Summary Table of Adjustments in
the AIC Threshold Amounts
In the following table we list the CYs
2010 through 2014 threshold amounts.
CY 2010
ALJ Hearing .........................................................................
Judicial Review ....................................................................
CY 2011
$130
1,260
$130
1,300
III. Collection of Information
Requirements
I. Background and Legislative
Authority
This document does not impose
information collection and
recordkeeping requirements.
Consequently, it need not be reviewed
by the Office of Management and
Budget under the authority of the
Paperwork Reduction Act of 1995 (44
U.S.C. 35).
Section 353 of the Public Health
Service Act (PHSA), as amended by the
Clinical Laboratory Improvement
Amendments of 1988 (CLIA) (Pub. L.
100–578), which was enacted on
October 31, 1988, generally provides
that no laboratory may perform tests on
human specimens for the diagnosis,
prevention or treatment of any disease
or impairment of, or assessment of the
health of, human beings unless it has a
certificate to perform that category of
tests issued by the Secretary of the
Department of Health and Human
Services (HHS). Under section 1861(s)
of the Social Security Act (the Act), the
Medicare program will only pay for
laboratory services if the laboratory has
a CLIA certificate. Section 1902(a)(9)(C)
of the Act requires that state Medicaid
plans pay only for laboratory services
furnished by CLIA-certified laboratories.
Thus, although subject to specified
exemptions and exceptions, laboratories
generally must have a current and valid
CLIA certificate to test human
specimens for medical purposes noted
above to be eligible for payment for
those tests from the Medicare or
Medicaid programs. Regulations
implementing section 353 of the PHSA
are contained in 42 CFR part 493.
Section 353(p) of the PHSA provides
for the exemption of laboratories from
CLIA requirements in states that enact
legal requirements that are equal to or
more stringent than CLIA’s statutory
and regulatory requirements. Section
353(p) of the PHSA is implemented in
subpart E of our regulations at 42 CFR
part 493. Sections 493.551 and 493.553
provide that we may exempt from CLIA
requirements, for a period not to exceed
6 years, all state-licensed or -approved
laboratories in a state if the state
licensure program meets the specified
conditions. Section 493.559 provides
that we will publish a notice in the
Federal Register when we grant
exemption to an approved state
licensure program. It also provides that
the notice will include the following:
• The basis for granting the
exemption.
(Catalog of Federal Domestic Assistance
Program No. 93.773 Medicare—Hospital
Insurance Program; and No. 93.774,
Medicare—Supplementary Medical
Insurance Program)
Dated: September 23, 2013.
Marilyn Tavenner,
Administrator, Centers for Medicare &
Medicaid Services.
[FR Doc. 2013–23655 Filed 9–26–13; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[CMS–3111–N]
Medicare, Medicaid, and CLIA
Programs; Clinical Laboratory
Improvement Amendments of 1988
Exemption of Laboratories Licensed
by the State of Washington
Centers for Medicare &
Medicaid Services (CMS), HHS.
ACTION: Notice.
AGENCY:
This notice announces that
laboratories located in and licensed by
the State of Washington that possess a
valid license under the Medical Test
Site law, Chapter 70.42 of the Revised
Code of Washington, are exempt from
the requirements of the Clinical
Laboratory Improvement Amendments
of 1988 (CLIA) for a period of 6 years.
DATES: The exemption granted by this
notice is effective from September 27,
2013 to September 27, 2019.
FOR FURTHER INFORMATION CONTACT:
Sandra Farragut, (410) 786–3531.
SUPPLEMENTARY INFORMATION:
pmangrum on DSK3VPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
14:21 Sep 26, 2013
Jkt 229001
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
CY 2012
$130
1,350
CY 2013
$140
1,400
CY 2014
$140
1,430
• A description of how the laboratory
requirements are equal to or more
stringent than those of CLIA.
• The term of approval, not to exceed
6 years.
State of Washington’s Application for
CLIA Exemption of Its Laboratories
The State of Washington has applied
for exemption of its laboratories from
CLIA program requirements. The State
of Washington submitted all of the
applicable information and attestations
required by § 493.551, § 493.553, and
§ 493.557 for state licensure programs
seeking exemption of their licensed
laboratories from CLIA program
requirements.
Examples of documents and
information submitted include: a
comparison of its laboratory licensure
requirements with comparable CLIA
condition-level requirements (that is, a
crosswalk); and a description of the
following: Its inspection process; its
proficiency testing monitoring process;
its data management and analysis
system; its investigative and response
procedures for complaints received
against laboratories; and its policy
regarding announced and unannounced
inspections.
CMS Analysis of Washington’s
Application and Supporting
Documentation
To determine whether we should
grant a CLIA exemption to laboratories
licensed by a state, we review the
application and additional
documentation that the state submits to
us and conducts a detailed and in-depth
comparison of the state licensure
program and CLIA’s statutory and
regulatory requirements to determine
whether the state program meets the
requirements at subpart E of part 493.
In summary, the state generally must
demonstrate that:
• It has state laws in effect that
provide for a state licensure program
that has requirements that are equal to
or more stringent than CLIA conditionlevel requirements for laboratories.
• It has implemented a state licensure
program with requirements that are
equal to or more stringent than the CLIA
condition-level requirements such that a
E:\FR\FM\27SEN1.SGM
27SEN1
pmangrum on DSK3VPTVN1PROD with NOTICES
Federal Register / Vol. 78, No. 188 / Friday, September 27, 2013 / Notices
laboratory licensed by the state program
would meet the CLIA condition-level
requirements if it were inspected against
those requirements.
• The requirements under that state
licensure program meet or exceed the
requirements of § 493.553, § 493.555,
and § 493.557(b) and is suitable for
approval by us under § 493.551. For
example, among other things, the
program would need to:
++ Demonstrate that it has
enforcement authority and
administrative structures and resources
adequate to enforce its laboratory
requirements.
++ Permit us or our agents to inspect
laboratories within the state.
++ Require laboratories within the
state to submit to inspections by us or
our agents as a condition of licensure.
++ Agree to pay any costs associated
with our activities to validate their state
licensure program as well as the state’s
pro rata share of the general overhead to
develop and implement CLIA as
specified in § 493.645(a), § 493.646(b),
and § 493.557(b).
++ Take appropriate enforcement
action against laboratories found by us
or our agents out of compliance with
requirements comparable to CLIA
condition-level requirements, as
specified in § 493.557(b).
As specified in our regulations at
§ 493.555 and § 493.557(b), our review
of a state licensure program includes
(but is not necessarily limited to) an
evaluation of the following:
• Whether the state’s requirements for
laboratories are equal to or more
stringent than the CLIA condition-level
requirements.
• The state’s inspection process
requirements to determine the
following:
++ The comparability of the full
inspection and complaint inspection
procedures to those of CMS.
++ The state’s enforcement
procedures for laboratories found to be
out of compliance with its requirements.
• The ability of the state to provide us
with electronic data and reports with
the adverse or corrective actions
resulting from proficiency testing (PT)
results that constitute unsuccessful
participation in CMS-approved PT
programs and with other data we
determine to be necessary for validation
review and assessment of the state’s
inspection process requirements.
• The state’s agreement with us to
ensure that the agreement obligates the
state to do the following:
++ Notify us within 30 days of the
action taken against any CLIA-exempt
laboratory that has had its licensure or
VerDate Mar<15>2010
14:21 Sep 26, 2013
Jkt 229001
approval withdrawn or revoked or been
in any way sanctioned.
++ Notify us within 10 days of any
deficiency identified in a CLIA-exempt
laboratory in cases when the deficiency
poses an immediate jeopardy to the
laboratory’s patients or a hazard to the
general public.
++ Notify each laboratory licensed by
the state under its approved state
licensure program within 10 days of a
withdrawal of our approval of the state’s
licensure program, and the resulting
loss of the laboratory’s exemption from
CLIA based on its licensure under that
program.
++ Provide us with written
notification of any changes in the state’s
licensure (or approval) and inspection
requirements.
++ Disclose to us or our agent any
laboratory’s PT results in accordance
with the state’s confidentiality
requirements.
++ Take appropriate enforcement
action against laboratories that we or
our agents find to be out of compliance
with CLIA condition-level requirements
in a validation survey, and report these
enforcement actions to us.
++ Notify us of all newly licensed
laboratories, and any changes in the
specialties and subspecialties for which
any laboratory performs testing, within
30 days.
++ Provide us, as requested,
inspection schedules for validation
purposes.
In keeping with the process described
above, we evaluated the application and
supporting materials that were
submitted by Washington State to verify
that the laboratories licensed through its
program will meet or exceed the
requirements of the following subparts
of part 493: Subpart H, Participation in
Proficiency Testing for Laboratories
Performing Nonwaived Testing; Subpart
J, Facility Administration for
Nonwaived Testing; Subpart K, Quality
Systems for Nonwaived Testing,
Subpart M, Personnel for Nonwaived
Testing; Subpart Q, Inspection; and
Subpart R, Enforcement Procedures.
We found that Washington State’s
laboratory licensure program
requirements mapped to all the CLIA
condition-level requirements. Its
licensure program’s inspection process
and proficiency testing monitoring
processes were adequate. Other
materials that were submitted
demonstrated compliance with the other
above-referenced requirements of
subpart E of part 493. As a result, we
concluded that the submitted
documents supported exempting
laboratories licensed under that program
from the CLIA program requirements.
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
59705
Furthermore, a review of our validation
inspections conducted by our regional
office in Seattle, Washington, supported
this conclusion.
The federal validation inspections of
CLIA-exempt laboratories, as specified
in § 493.563, were conducted on a
representative sample basis, as well as
in response to any substantial
allegations of noncompliance
(complaint inspections). The outcome of
those validation inspections has been,
and will continue to be our principal
tool for verifying that the laboratories
located in, and licensed by the state are
in compliance with CLIA requirements.
Our regional office in Seattle,
Washington, has conducted validation
inspections of a representative sample
(approximately 5 percent) of the
laboratories inspected by the
Washington State Office of Laboratory
Quality Assurance (LQA). The
validation inspections were primarily of
the concurrent type; that is, our
surveyors accompanied Washington
State’s inspectors, each inspecting
against his or her agency’s respective
regulations. Analysis of the validation
data revealed no significant differences
between the state and federal findings.
The validation surveys verified that the
State of Washington inspection process
covers all CLIA conditions applicable to
each laboratory being inspected and also
verified that the state laboratory
licensure requirements meet or exceed
CLIA condition-level requirements. Our
validation surveys found the state
inspectors highly skilled and qualified.
The LQA inspected laboratories in a
timely fashion; that is, all laboratories
were inspected within the required 24month cycle. All parameters monitored
by our Seattle office to date indicate that
the State of Washington is meeting all
requirements for approval of CLIA
exemption. This federal monitoring will
continue as an on-going process.
Conclusion
Based on review of the documents
submitted by the Washington state
licensure program pursuant to the
requirements of subpart E of part 493, as
well as the outcome of the validation
inspections conducted by our regional
office in Seattle, we find that the State
of Washington’s licensure program
meets the requirements of 42 CFR
493.551(a), and that, as a result, we may
exempt from CLIA program
requirements all state-licensed or
-approved laboratories.
Approval of the CLIA exemption for
laboratories located in and licensed by
the State of Washington laboratory
licensure program is subject to removal
if we determine that the outcome of a
E:\FR\FM\27SEN1.SGM
27SEN1
59706
Federal Register / Vol. 78, No. 188 / Friday, September 27, 2013 / Notices
comparability review or a validation
review inspection is not acceptable, as
described under § 493.573 and
§ 493.575, or if the State of Washington
fails to pay the required fee every 2
years as required under § 493.646.
Laboratory Data
In accordance with our regulations at
§ 493.557(b)(8), the approval of this
exemption for laboratories located in
and licensed by the State of Washington
is conditioned on the State of
Washington’s continued compliance
with the assertions made in its
application, especially the provision of
information to us about changes to a
laboratory’s specialties or subspecialties
based on the state’s survey, and changes
to a laboratory’s certification status,
such as a change from a CLIA certificate
of compliance to a CLIA certificate of
waiver.
pmangrum on DSK3VPTVN1PROD with NOTICES
Required Administrative Actions
CLIA is a user-fee funded program.
The registration fee paid by laboratories
is intended to cover the cost of the
development and administration of the
program. However, when a state’s
application for exemption is approved,
we do not charge a fee to laboratories in
the state. The state’s share of the costs
associated with CLIA must be collected
from the state, as specified in § 493.645.
The State of Washington must pay for
the following:
• Costs of federal inspections of
laboratories in the state to verify that
Washington State’s laboratory licensure
program requirements are equivalent to
or more stringent than those in the CLIA
program, and that they are enforced in
an appropriate manner. The average
federal hourly rate is multiplied by the
total hours required to perform federal
validation surveys within the state.
• Costs incurred for federal surveys,
including investigations of complaints
that are substantiated. We will bill the
State of Washington on a semiannual
basis.
• The State of Washington’s
proportionate share of the costs
associated with establishing,
maintaining, and improving the CLIA
computer system, based on the portion
of those services from which the State
of Washington received direct benefit or
which contributed to the CLIA program
in the state. Thus, the State of
Washington is being charged for a
portion of our direct and indirect costs
of administering the CLIA program.
Such costs will be incurred by CMS, the
Centers for Disease Control and
Prevention (CDC), the Food and Drug
Administration (FDA) and contractors
VerDate Mar<15>2010
14:21 Sep 26, 2013
Jkt 229001
working on behalf of these respective
agencies.
To estimate the State of Washington’s
proportionate share of the general
overhead costs to develop and
implement CLIA, we determined the
ratio of laboratories in the state to the
total number of laboratories nationally.
Approximately 1.5 percent of the
registered laboratories are in the State of
Washington. We determined that a
corresponding percentage of the
applicable CMS, CDC, FDA, and their
respective contractor costs should be
borne by the State of Washington.
The State of Washington has agreed to
pay the state’s pro rata share of the
anticipated overhead costs and costs of
actual validation (including complaint
investigation surveys). A final
reconciliation for all laboratories and all
expenses will be made. We will
reimburse the state for any overpayment
or bill it for any balance.
II. Approval
In light of the foregoing, we grant
approval of the State of Washington’s
laboratory licensure program under
subpart E. All laboratories located in
and licensed by the State of Washington
under the Medical Test Site law,
Chapter 70.42 of the Revised Code of
Washington, are CLIA-exempt for all
specialties and subspecialties until
September 27, 2019.
FOR FURTHER INFORMATION CONTACT:
Katharine Neckers, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Building 51, Rm. 4259,
301–796–3339, email:
Katharine.Neckers@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In FR
Doc. 2013–20215, appearing on page
51192 in the Federal Register of August
20, 2013, the following correction is
made:
On page 51194, in the second column,
under ‘‘IV. Process for Applying to
Participate in the Pilot,’’ in the third full
paragraph, the sentence that reads ‘‘For
communications other than the
submission of the SSCPP application
(Form FDA 3676), please contact the
CDER SSCPP mailbox at
SSCPPMailbox@fda.hhs.gov’’ is
corrected to read ‘‘For communications
other than the submission of the SSCPP
application (Form FDA 3676), please
contact the CDER SSCPP mailbox at
CDERSSCPP@fda.hhs.gov.’’
Dated: September 24, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013–23563 Filed 9–26–13; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Authority: Section 353(p) of the Public
Health Service Act (42 U.S.C. 263a).
National Institutes of Health
Dated: August 8, 2013.
Marilyn Tavenner,
Administrator, Centers for Medicare &
Medicaid Services.
Proposed Collection; 30-Day Comment
Request; Evaluation of a Kidney
Disease Education and Awareness
Program in the Hispanic Community
[FR Doc. 2013–23659 Filed 9–26–13; 8:45 am]
SUMMARY:
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2008–N–0656]
Secure Supply Chain Pilot Program;
Correction
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice; correction.
The Food and Drug
Administration (FDA) is correcting a
document that appeared in the Federal
Register of August 20, 2013 (78 FR
51192). The document announced the
start of the Secure Supply Chain Pilot
Program (SSCPP). The document was
published with an incorrect email
address for the SSCPP mailbox. This
document corrects that error.
SUMMARY:
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
Under the provisions of
Section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Institutes of Health (NIH) has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below. This proposed information
collection was previously published in
the Federal Register on July 19, 2013,
Volume 78, pages 43214–43215, and
allowed 60-days for public comment.
One public comment was received. The
purpose of this notice is to allow an
additional 30 days for public comment.
The National Kidney Disease Education
Program, the National Institute of
Diabetes and Digestive and Kidney
Diseases, the National Institutes of
Health (NIH), may not conduct or
sponsor, and the respondent is not
required to respond to, an information
collection that has been extended,
revised, or implemented on or after
October 1, 1995, unless it displays a
currently valid OMB control number.
E:\FR\FM\27SEN1.SGM
27SEN1
Agencies
[Federal Register Volume 78, Number 188 (Friday, September 27, 2013)]
[Notices]
[Pages 59704-59706]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-23659]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[CMS-3111-N]
Medicare, Medicaid, and CLIA Programs; Clinical Laboratory
Improvement Amendments of 1988 Exemption of Laboratories Licensed by
the State of Washington
AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice announces that laboratories located in and
licensed by the State of Washington that possess a valid license under
the Medical Test Site law, Chapter 70.42 of the Revised Code of
Washington, are exempt from the requirements of the Clinical Laboratory
Improvement Amendments of 1988 (CLIA) for a period of 6 years.
DATES: The exemption granted by this notice is effective from September
27, 2013 to September 27, 2019.
FOR FURTHER INFORMATION CONTACT: Sandra Farragut, (410) 786-3531.
SUPPLEMENTARY INFORMATION:
I. Background and Legislative Authority
Section 353 of the Public Health Service Act (PHSA), as amended by
the Clinical Laboratory Improvement Amendments of 1988 (CLIA) (Pub. L.
100-578), which was enacted on October 31, 1988, generally provides
that no laboratory may perform tests on human specimens for the
diagnosis, prevention or treatment of any disease or impairment of, or
assessment of the health of, human beings unless it has a certificate
to perform that category of tests issued by the Secretary of the
Department of Health and Human Services (HHS). Under section 1861(s) of
the Social Security Act (the Act), the Medicare program will only pay
for laboratory services if the laboratory has a CLIA certificate.
Section 1902(a)(9)(C) of the Act requires that state Medicaid plans pay
only for laboratory services furnished by CLIA-certified laboratories.
Thus, although subject to specified exemptions and exceptions,
laboratories generally must have a current and valid CLIA certificate
to test human specimens for medical purposes noted above to be eligible
for payment for those tests from the Medicare or Medicaid programs.
Regulations implementing section 353 of the PHSA are contained in 42
CFR part 493.
Section 353(p) of the PHSA provides for the exemption of
laboratories from CLIA requirements in states that enact legal
requirements that are equal to or more stringent than CLIA's statutory
and regulatory requirements. Section 353(p) of the PHSA is implemented
in subpart E of our regulations at 42 CFR part 493. Sections 493.551
and 493.553 provide that we may exempt from CLIA requirements, for a
period not to exceed 6 years, all state-licensed or -approved
laboratories in a state if the state licensure program meets the
specified conditions. Section 493.559 provides that we will publish a
notice in the Federal Register when we grant exemption to an approved
state licensure program. It also provides that the notice will include
the following:
The basis for granting the exemption.
A description of how the laboratory requirements are equal
to or more stringent than those of CLIA.
The term of approval, not to exceed 6 years.
State of Washington's Application for CLIA Exemption of Its
Laboratories
The State of Washington has applied for exemption of its
laboratories from CLIA program requirements. The State of Washington
submitted all of the applicable information and attestations required
by Sec. 493.551, Sec. 493.553, and Sec. 493.557 for state licensure
programs seeking exemption of their licensed laboratories from CLIA
program requirements.
Examples of documents and information submitted include: a
comparison of its laboratory licensure requirements with comparable
CLIA condition-level requirements (that is, a crosswalk); and a
description of the following: Its inspection process; its proficiency
testing monitoring process; its data management and analysis system;
its investigative and response procedures for complaints received
against laboratories; and its policy regarding announced and
unannounced inspections.
CMS Analysis of Washington's Application and Supporting Documentation
To determine whether we should grant a CLIA exemption to
laboratories licensed by a state, we review the application and
additional documentation that the state submits to us and conducts a
detailed and in-depth comparison of the state licensure program and
CLIA's statutory and regulatory requirements to determine whether the
state program meets the requirements at subpart E of part 493.
In summary, the state generally must demonstrate that:
It has state laws in effect that provide for a state
licensure program that has requirements that are equal to or more
stringent than CLIA condition-level requirements for laboratories.
It has implemented a state licensure program with
requirements that are equal to or more stringent than the CLIA
condition-level requirements such that a
[[Page 59705]]
laboratory licensed by the state program would meet the CLIA condition-
level requirements if it were inspected against those requirements.
The requirements under that state licensure program meet
or exceed the requirements of Sec. 493.553, Sec. 493.555, and Sec.
493.557(b) and is suitable for approval by us under Sec. 493.551. For
example, among other things, the program would need to:
++ Demonstrate that it has enforcement authority and administrative
structures and resources adequate to enforce its laboratory
requirements.
++ Permit us or our agents to inspect laboratories within the
state.
++ Require laboratories within the state to submit to inspections
by us or our agents as a condition of licensure.
++ Agree to pay any costs associated with our activities to
validate their state licensure program as well as the state's pro rata
share of the general overhead to develop and implement CLIA as
specified in Sec. 493.645(a), Sec. 493.646(b), and Sec. 493.557(b).
++ Take appropriate enforcement action against laboratories found
by us or our agents out of compliance with requirements comparable to
CLIA condition-level requirements, as specified in Sec. 493.557(b).
As specified in our regulations at Sec. 493.555 and Sec.
493.557(b), our review of a state licensure program includes (but is
not necessarily limited to) an evaluation of the following:
Whether the state's requirements for laboratories are
equal to or more stringent than the CLIA condition-level requirements.
The state's inspection process requirements to determine
the following:
++ The comparability of the full inspection and complaint
inspection procedures to those of CMS.
++ The state's enforcement procedures for laboratories found to be
out of compliance with its requirements.
The ability of the state to provide us with electronic
data and reports with the adverse or corrective actions resulting from
proficiency testing (PT) results that constitute unsuccessful
participation in CMS-approved PT programs and with other data we
determine to be necessary for validation review and assessment of the
state's inspection process requirements.
The state's agreement with us to ensure that the agreement
obligates the state to do the following:
++ Notify us within 30 days of the action taken against any CLIA-
exempt laboratory that has had its licensure or approval withdrawn or
revoked or been in any way sanctioned.
++ Notify us within 10 days of any deficiency identified in a CLIA-
exempt laboratory in cases when the deficiency poses an immediate
jeopardy to the laboratory's patients or a hazard to the general
public.
++ Notify each laboratory licensed by the state under its approved
state licensure program within 10 days of a withdrawal of our approval
of the state's licensure program, and the resulting loss of the
laboratory's exemption from CLIA based on its licensure under that
program.
++ Provide us with written notification of any changes in the
state's licensure (or approval) and inspection requirements.
++ Disclose to us or our agent any laboratory's PT results in
accordance with the state's confidentiality requirements.
++ Take appropriate enforcement action against laboratories that we
or our agents find to be out of compliance with CLIA condition-level
requirements in a validation survey, and report these enforcement
actions to us.
++ Notify us of all newly licensed laboratories, and any changes in
the specialties and subspecialties for which any laboratory performs
testing, within 30 days.
++ Provide us, as requested, inspection schedules for validation
purposes.
In keeping with the process described above, we evaluated the
application and supporting materials that were submitted by Washington
State to verify that the laboratories licensed through its program will
meet or exceed the requirements of the following subparts of part 493:
Subpart H, Participation in Proficiency Testing for Laboratories
Performing Nonwaived Testing; Subpart J, Facility Administration for
Nonwaived Testing; Subpart K, Quality Systems for Nonwaived Testing,
Subpart M, Personnel for Nonwaived Testing; Subpart Q, Inspection; and
Subpart R, Enforcement Procedures.
We found that Washington State's laboratory licensure program
requirements mapped to all the CLIA condition-level requirements. Its
licensure program's inspection process and proficiency testing
monitoring processes were adequate. Other materials that were submitted
demonstrated compliance with the other above-referenced requirements of
subpart E of part 493. As a result, we concluded that the submitted
documents supported exempting laboratories licensed under that program
from the CLIA program requirements. Furthermore, a review of our
validation inspections conducted by our regional office in Seattle,
Washington, supported this conclusion.
The federal validation inspections of CLIA-exempt laboratories, as
specified in Sec. 493.563, were conducted on a representative sample
basis, as well as in response to any substantial allegations of
noncompliance (complaint inspections). The outcome of those validation
inspections has been, and will continue to be our principal tool for
verifying that the laboratories located in, and licensed by the state
are in compliance with CLIA requirements.
Our regional office in Seattle, Washington, has conducted
validation inspections of a representative sample (approximately 5
percent) of the laboratories inspected by the Washington State Office
of Laboratory Quality Assurance (LQA). The validation inspections were
primarily of the concurrent type; that is, our surveyors accompanied
Washington State's inspectors, each inspecting against his or her
agency's respective regulations. Analysis of the validation data
revealed no significant differences between the state and federal
findings. The validation surveys verified that the State of Washington
inspection process covers all CLIA conditions applicable to each
laboratory being inspected and also verified that the state laboratory
licensure requirements meet or exceed CLIA condition-level
requirements. Our validation surveys found the state inspectors highly
skilled and qualified. The LQA inspected laboratories in a timely
fashion; that is, all laboratories were inspected within the required
24-month cycle. All parameters monitored by our Seattle office to date
indicate that the State of Washington is meeting all requirements for
approval of CLIA exemption. This federal monitoring will continue as an
on-going process.
Conclusion
Based on review of the documents submitted by the Washington state
licensure program pursuant to the requirements of subpart E of part
493, as well as the outcome of the validation inspections conducted by
our regional office in Seattle, we find that the State of Washington's
licensure program meets the requirements of 42 CFR 493.551(a), and
that, as a result, we may exempt from CLIA program requirements all
state-licensed or -approved laboratories.
Approval of the CLIA exemption for laboratories located in and
licensed by the State of Washington laboratory licensure program is
subject to removal if we determine that the outcome of a
[[Page 59706]]
comparability review or a validation review inspection is not
acceptable, as described under Sec. 493.573 and Sec. 493.575, or if
the State of Washington fails to pay the required fee every 2 years as
required under Sec. 493.646.
Laboratory Data
In accordance with our regulations at Sec. 493.557(b)(8), the
approval of this exemption for laboratories located in and licensed by
the State of Washington is conditioned on the State of Washington's
continued compliance with the assertions made in its application,
especially the provision of information to us about changes to a
laboratory's specialties or subspecialties based on the state's survey,
and changes to a laboratory's certification status, such as a change
from a CLIA certificate of compliance to a CLIA certificate of waiver.
Required Administrative Actions
CLIA is a user-fee funded program. The registration fee paid by
laboratories is intended to cover the cost of the development and
administration of the program. However, when a state's application for
exemption is approved, we do not charge a fee to laboratories in the
state. The state's share of the costs associated with CLIA must be
collected from the state, as specified in Sec. 493.645.
The State of Washington must pay for the following:
Costs of federal inspections of laboratories in the state
to verify that Washington State's laboratory licensure program
requirements are equivalent to or more stringent than those in the CLIA
program, and that they are enforced in an appropriate manner. The
average federal hourly rate is multiplied by the total hours required
to perform federal validation surveys within the state.
Costs incurred for federal surveys, including
investigations of complaints that are substantiated. We will bill the
State of Washington on a semiannual basis.
The State of Washington's proportionate share of the costs
associated with establishing, maintaining, and improving the CLIA
computer system, based on the portion of those services from which the
State of Washington received direct benefit or which contributed to the
CLIA program in the state. Thus, the State of Washington is being
charged for a portion of our direct and indirect costs of administering
the CLIA program. Such costs will be incurred by CMS, the Centers for
Disease Control and Prevention (CDC), the Food and Drug Administration
(FDA) and contractors working on behalf of these respective agencies.
To estimate the State of Washington's proportionate share of the
general overhead costs to develop and implement CLIA, we determined the
ratio of laboratories in the state to the total number of laboratories
nationally. Approximately 1.5 percent of the registered laboratories
are in the State of Washington. We determined that a corresponding
percentage of the applicable CMS, CDC, FDA, and their respective
contractor costs should be borne by the State of Washington.
The State of Washington has agreed to pay the state's pro rata
share of the anticipated overhead costs and costs of actual validation
(including complaint investigation surveys). A final reconciliation for
all laboratories and all expenses will be made. We will reimburse the
state for any overpayment or bill it for any balance.
II. Approval
In light of the foregoing, we grant approval of the State of
Washington's laboratory licensure program under subpart E. All
laboratories located in and licensed by the State of Washington under
the Medical Test Site law, Chapter 70.42 of the Revised Code of
Washington, are CLIA-exempt for all specialties and subspecialties
until September 27, 2019.
Authority: Section 353(p) of the Public Health Service Act (42
U.S.C. 263a).
Dated: August 8, 2013.
Marilyn Tavenner,
Administrator, Centers for Medicare & Medicaid Services.
[FR Doc. 2013-23659 Filed 9-26-13; 8:45 am]
BILLING CODE 4120-01-P